| ALLE |
Report |
Q2 Adjusted EPS |
BEAT |
pred ~$2.26 vs. cons ~$2.22 |
MEDIUM |
| ALLE |
Report |
Q2 Total organic revenue growth |
IN-LINE |
pred ~+3.3% vs. cons ~+3.0% |
LOW |
| ALLE |
Report |
Q2 Adjusted operating margin |
MISS |
pred ~23.2% vs. cons ~23.6% |
MEDIUM |
| ALLE |
Guide |
FY2026 Adjusted EPS guide |
BETTER |
guide ~$8.80 midpoint (raise from $8.70-$8.90) vs. cons ~$8.73 (FY2026) |
LOW |
| ALLE |
Guide |
FY2026 organic revenue growth guide |
UNCHANGED |
guide ~2-4% (mid ~3%) vs. cons ~3% (FY2026) |
MEDIUM |
| ALLE |
Guide |
International organic/margin recovery (ERP) commentary |
UNKNOWN |
guide International margin ~9-10%/organic still soft in Q2 vs. cons ~10% recovery (H2 2026) |
LOW |
| ALLE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| ALLE |
Return |
5-day cumulative residual |
+1.5% (STABILIZE) |
Beaten-down 'show-me' stock at ~16x with low beta (~0.8) and skepticism already priced after the Q1 -7% miss reaction. A modest EPS beat plus a tariff-pricing-driven guide raise (2025 playbook) should spark a relief pop. But the raise is largely mechanical/H2-loaded, Q2 margins likely still down YoY (DCI drag, peso FX, PPII), and the International ERP recovery remains unproven — so out-period estimates barely move up. Initial gain holds but does not compound: gains stabilize as investors wait for actual H2 delivery. |
LOW |